

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
26 December 2019 (26.12.2019)



(10) International Publication Number
WO 2019/243303 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) *A61K 31/404* (2006.01)
C07D 471/04 (2006.01) *A61K 31/4439* (2006.01)
A61P 25/00 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2019/065967

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:

18 June 2019 (18.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))

(30) Priority Data:

18178429.9 19 June 2018 (19.06.2018) EP
19157936.6 19 February 2019 (19.02.2019) EP

(71) Applicant: **UCB PHARMA GMBH** [DE/DE]; Alfred-Nobel-Strasse 10, 40789 Monheim (DE).

(72) Inventors: **PEGURIER, Cécile**; c/o IPD, UCB Biopharma SPRL, Allée de la Recherche 60, 1070 Brussels (BE). **PROVINS, Laurent**; c/o IPD, UCB Biopharma SPRL, Allée de la Recherche 60, 1070 Brussels (BE). **CARDENAS, Alvaro**; c/o IPD, UCB Biopharma SPRL, Allée de la Recherche 60, 1070 Brussels (BE). **LEDECQ, Marie**; c/o IPD, UCB Biopharma SPRL, Allée de la Recherche 60, 1070 Brussels (BE). **MUELLER, Christa E.**; Buschstrasse 52, 53113 Bonn (DE). **HOCKEMEYER, Joerg**; Bonmer Talweg 30, 53113 Bonn (DE). **EL-TAYEB, Ali**; Endenicher Strasse 165, 53115 Bonn (DE). **BOSHITA, Nader**; Endenicher Strasse 185, 53115 Bonn (DE). **RASHED, Mahmoud**; Jagdweg 22, 53115 Bonn (DE).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; c/o UCB Pharma GmbH, Alfred-Nobel-Strasse 10, 40789 Monheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES

(57) Abstract: The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

WO 2019/243303 A1